Loading...
Market
Argenx stock price performance by end of 2024?
5
Resolution / Starting Odds
Stock price increases by over 50% • 33%
Stock price remains within 20% of current value • 34%
Stock price decreases by over 20% • 33%
Public stock market data (e.g., NASDAQ)
Story
Argenx's Vyvgart Hytrulo Shot Gains Second FDA Approval for CIDP with Halozyme's ENHANZE
Jun 21, 2024, 09:10 PM
Argenx's Vyvgart Hytrulo shot has received its second US FDA approval to treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare nervous system disorder. This approval marks a significant milestone for the biotechnology firm, which has faced a series of setbacks. The Vyvgart Hytrulo shot is co-formulated with Halozyme's ENHANZE technology. This label expansion into CIDP adds to Argenx's growth prospects ahead of more clinical milestones anticipated in 2024.
View original story
Similar markets
Below $30 • 25%
$30-$40 • 25%
$40-$50 • 25%
Above $50 • 25%
Below $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
Above $100 • 25%
Below $50 • 25%
$50-$74.99 • 25%
$75-$99.99 • 25%
$100 or higher • 25%
ABBV up, GMAB up • 25%
ABBV up, GMAB down • 25%
ABBV down, GMAB up • 25%
ABBV down, GMAB down • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Less than 10% • 33%
10% to 25% • 33%
More than 25% • 33%
Recover to pre-incident levels • 33%
Exceed pre-incident levels • 33%
Remain below pre-incident levels • 34%
Above 10% of pre-fire level • 33%
Within 10% of pre-fire level • 33%
Below 10% of pre-fire level • 33%
Increase by 0-10% • 25%
Increase by more than 10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Below $166 • 33%
$166 to $213 • 33%
Above $213 • 34%